Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ: NVCR )

30.07 -0.73 (-2.39%)
Streaming Delayed Price Updated: 10:18 AM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
This Company's Device is Becoming Essential to Cancer Treatment -- Why Is the Stock Slumping?
Is it time to buy this stock nearly at its 52 week low? 
Via The Motley Fool
Cramer Likes Ford, But Suggests Waiting For Dips To Buy These Stocks
On Friday's "Mad Money Lightning ... 
Via Benzinga
Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
From Novocure
Via Business Wire
Novocure to Report Third Quarter 2021 Financial Results
From Novocure
Via Business Wire
NovoCure: Q2 Earnings Insights
Shares of NovoCure (NASDAQ:NVCR) remained unaffected after the company reported Q2 results. Quarterly Results Earnings per share were down 800.00% over the past year to ($0... 
Via Benzinga
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Novocure To Test Its Tumor Treating Fields With Roche's Tecentriq In Pancreatic Cancer
Novocure Ltd (NASDAQ: NVCR) has entered into a clinical trial collaboration agreement with Roche Holdings AG (OTC: RHHBY) to develop Tumor Treating... 
Via Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
Pressure Day
Today a recovery came to markets with a particular impact on uranium shares. 
Via Talk Markets
A Weak Week
Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. 
Via Talk Markets
Delta Variant Fears Continue
The jobless level fell to 310,000 whereas the consensus forecast was for 335,000, so risks of inflation are higher. 
Via Talk Markets
This Promising Healthcare Stock Is Down 50% From Its Highs; Should You Buy the Dip?
Novocure has been fantastic for investors, up over 1,600% in the past five years. But in the past six months, shareholders have been on a roller coaster. 
Via The Motley Fool
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
From Novocure
Via Business Wire
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
From Novocure
Via Business Wire
Novocure Appoints Bill Burke as Chief Human Resources Officer
From Novocure
Via Business Wire
Friday the Thirteenth
The stock week in points eastward was mixed. The USA markets face a bear correction. 
Via Talk Markets
What's Next for Novocure?
The company has several key data readouts on the way. 
Via The Motley Fool
Delta Outbreak
The US market was droopy because of poor private sector jobless numbers. 
Via Talk Markets
Cramer Advises Viewers On Palantir, SoFi And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't understand why is MKS Instruments, Inc. (NASDAQ: MKSI) trading so cheap. He would be a buyer.... 
Via Benzinga
Know When To Hold 'Em, Know When To Fold 'Em ...
A long Monday list identifying some sensible and some impenetrable moves behind today's market in our stocks. 
Via Talk Markets
Here's Why Novocure Dipped 19% This Week
Uptake of the company's revolutionary disease-controlling device isn't progressing as quickly as expected. 
Via The Motley Fool
News Overload
Today US markets managed a rally despite misses in both the growth and employment data. 
Via Talk Markets
70 Biggest Movers From Yesterday
Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently reported closing of $12.5 million private... 
Via Benzinga
Why Novocure Tanked on Thursday
Investors are seeing red in the company's latest earnings report. 
Via The Motley Fool
NovoCure (NVCR) Q2 2021 Earnings Call Transcript
NVCR earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Novocure Stock Dips As Q2 Earnings Trail Estimates; Higher Costs Hit Bottom Line
Novocure Ltd (NASDAQ: NVCR) posted a net loss of $14.6 million in Q2, compared to a net income of $1.7 million a year ago. EPS came in at $(0.14), missing the consensus... 
Via Benzinga
Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.